Cargando…
Molecular Testing in Ovarian Tumours: Challenges from the Pathologist’s Perspective
The use of molecular testing to direct diagnosis and treatment options in ovarian tumours has rapidly expanded in recent years, in particular with regard to the recommendation for routine homologous recombination deficiency (HRD) testing in all patients with high-grade ovarian epithelial tumours. Th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297009/ https://www.ncbi.nlm.nih.gov/pubmed/37370967 http://dx.doi.org/10.3390/diagnostics13122072 |